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Isolated rat hepatocytes were used to determine the cytotoxicity of peripheral blood 
mononuclear cells (PBM) from patients with alcoholic liver disease (ALD) and chronic 
active hepatitis (CAH). The specificity of the cytotoxic effect on liver cells was moni- 
tored using rat kidney cells. PBM from patients with CAH and ALD showed increased 
spontaneous cell-mediated cytolysis (SCMC) for hepatocytes. The SCMC against kidney 
cells was comparable for the patient groups and controls. Incubation of liver cells with 
antibody to human liver-specific protein significantly increased the cytotoxic activity of 
control PBM but did not block cytotoxicity by PBM of patients with CAH. Incubation of 
PBM from untreated CAH patients with thymosin fraction 5, a polypeptide extract of the 
thymus gland, significantly lowered cytotoxicity. Our findings suggest that rat liver cells 
provide a model for studies of cell-mediated immunity in human liver disease and that 
thymosin fraction 5 decreases the cytotoxic activity of sensitized lymphocytes in CAH. 
INTRODUCTION 
The cell-mediated immune system has been implicated as a possible mechanism 
for the hepatocellular destruction observed in a number of acute and chronic liver 
diseases (l-5). A variety of experimental models have been utilized to demon- 
strate cell-mediated cytotoxicity in patients with alcoholic liver disease, acute 
viral hepatitis, and chronic active hepatitis. The target cells for these studies have 
included Chang cells (6- lo), rabbit and baboon hepatocytes (11- 18), autologous 
human liver cells (8, 11, 12, 19, 20) and avian erythrocytes coated with purified 
liver cell membrane lipoprotein (21). The use of Chang liver cells has been ques- 
tioned, prompted by concerns that these cells may no longer possess important 
antigenic determinants found on human, rabbit, and rat liver cells (22). Autolo- 
gous human liver cells are difficult to obtain in sufficient number and are often 
unavailable in selected patients. Additionally, few of the studies to date have 
attempted to determine the specificity of cell-mediated cytotoxicity for the target 
liver cell. 
We used monolayer cultures of isolated rat hepatocytes to study the im- 
munologic mechanisms associated with the destruction of hepatocytes in alcoholic 
liver disease and chronic liver disease. Rat hepatocytes can be obtained in suffi- 
cient numbers and when grown in primary monolayer culture do not proliferate for 
several days. In addition, these cells demonstrate specific functions of hepato- 
cytes seen in vivo (23). Close immunological cross reactivity has been demon- 
strated between the hepatocyte membrane liver-specific protein of rats and hu- 
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mans (22, 24). Rat kidney cells, also grown in monolayer cultures, were used to 
assess the specificity of the peripheral blood mononuclear cell (PBM) interaction 
for liver parenchymal cells. The role of antibodies directed against liver-specific 
protein (LSP) in cell-mediated cytotoxicity was also examined. 
Finally, PBM pretreated with thymosin fraction 5 were added to the hepatocyte 
monolayers to assess the possible effect of this immunomodulator on cell- 
mediated cytotoxicity. Thymosin, a polypeptide extract of the thymus gland, has 
been shown to induce the maturation of undifferentiated lymphocytes predeter- 
mined to follow the T-cell limb of the immune system. In addition, thymosin can 
influence the number and function of selective subsets of T cells including the 
immunoregulatory suppressor or helper cells (25). 
PATIENTS AND METHODS 
Patient and control subjects. A total of 50 patients were evaluated in the present 
study. Seven male patients, ages 32-68, had compensated alcoholic cirrhosis 
(CAC) on the basis of biopsy evidence of micronodular cirrhosis without superirn- 
posed alcoholic hepatitis (26), previous heavy alcohol intake, and demonstrated 
clinical and laboratory findings compatible with quiescent disease. 
Ten patients consisting of nine males and one female, ages 35-58, had alcoholic 
hepatitis (AH). Although biopsies were sought, frequent coagulation deficiencies 
and poor clinical status precluded this procedure in 4 of the 10 patients. In them, 
the diagnosis of AH was based on clinical and laboratory findings similar to that 
used in a previous study of adrenocorticosteroid therapy in AH (27). Biopsies 
were accomplished in six patients and the diagnosis of AH (26) was histologically 
confirmed in each case. 
Eight patients had the characteristic histologic features of chronic persistent 
hepatitis (CPH) (26) and three patients had unresolved hepatitis (26) (Table 1). 
Twenty patients had chronic active hepatitis (CAH) by clinical, biochemical, and 
histological criteria (26). Two additional patients with previous CAH were in 
remission and had the histologic finding of CPH following cessation of prednisone 
therapy at least 2 months earlier (Table 1). 
A total of 34 normal control subjects (27 males, 7 females; ages 20-51) were 
studied. The control subjects were divided into two groups. Twenty-one controls 
(CT-l) were used to compute the cytotoxicity ratio (CR) (11) for each of 21 
experiments. The number of patients evaluated in each experiment ranged from 
one to four. A second group of 13 control subjects (CT-2) were evaluated in 
random fashion throughout the study to monitor the CT- 1 responses. In addition, 
the CR observed in the CT-2 was compared to the CR of the patient groups for the 
statistical analysis. All control subjects were healthy volunteers not known to 
have current or previous liver disease. Controls and patients with malignancy, 
with previous known immunodeficiency, with a history of recent viral upper respi- 
ratory illness, or recipients of blood transfusions within 4 weeks of the study were 
excluded. 
Preparation ofliver cells. Monolayer cultures of isolated rat liver parenchymal 
cells were prepared as previously described (28). Briefly, sodium nembutal (10 
mg/lOO g body wt) was injected intraperitoneally into male Sprague-Dawley rats 
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(200-250 g). The liver was perfused in situ with medium, consisting of calcium- 
free Hank’s balanced salt solution (HBSS) containing 10 milliunits of insulin/ml, 
0.5% bovine serum albumin (Calbiochem, La Jolla, Cahf.), 2 units/ml of heparin, 
1 .O mM of MgSO,, 100 pg/ml of streptomycin, and 100 units/ml of penicillin. The 
medium was maintained at 37”C, gassed with 95% 0,/5% COZ, and perfused 
through the liver with a polystatic pump for 15 min. 
Enzyme perfusion medium was then infused for 20 min. This medium resembled 
the original perfusion medium, with the exception that heparin was absent and 
collagenase II, 0.05% (Worthington Chemicals, Freehold, N.J.) was added. The 
liver was transferred to a sterile disposable (100 x 10 mm) petri dish in an ice bath. 
Glisson’s capsule was cut and the cells gently dispersed. The cell suspension 
was filtered in sequence through a 253~pm mesh and then 64-pm mesh nylon 
gauze (Tobler, Ernst and Traber, Inc., Elmsford, N.Y.) into a sterile plastic cen- 
trifuge tube in an ice bath. 
The cell suspension was centrifuged at 1OOg for 15 min at 4°C and the supema- 
tant discarded. The pellet was then washed twice with ice-cold perfusion medium, 
centrifuged at 12Og for 10 min, and resuspended in Ham’s F-12 medium (Microbi- 
ological Associates, Bethesda, Md.) buffered with sodium bicarbonate at pH 7.4 
and containing heat-inactivated, dialyzed fetal calf serum (FCS) (Reheis Chemical 
Co., Phoenix, Ariz.), 0.5 kg (11.9 milliunits) of insulin, 100 units of penicillin, and 
100 pg of streptomycin/ml. The percentage of viable cells ranged between 96 and 
98% by trypan blue exclusion. Antisera to rat membrane LSP (generously pro- 
vided by Dr. K. H. Meyer zum Btischenfelde) was used as an organ marker and 
revealed that greater than 99% of the cells isolated were hepatocytes, using the 
indirect immunofluorescent technique as described previously (22). 
Viable cells (1 x 105) were seeded into each well of a Falcon multiwell tissue 
culture plate (Falcon 3008) (at a density of 5 x lo4 cells/cm2) in a volume of 1 ml of 
Ham’s F-12. The cells were incubated at 37°C in a humidified atmosphere of 5% 
CO, in air. 
After 6 hr incubation, the medium was changed. At 18 hr the Ham’s F-12 was 
replaced by Waymouth HI-WO,/BA,,,, (International Scientific Industries, Gary, 
Ind.) culture medium. This allowed continuation of the culture in a serum-free 
milieu. This medium consisted of Waymouth’s medium MB752/1 with 5 pg (11.9 
milliunits) of insulin, 100 units of penicillin, and 100 pg of streptomycin/ml. The 
medium was changed daily. By the third day of incubation a monolayer was noted 
to cover the bottom of the well. Microscopic examination of each well was done to 
insure the presence of a uniform monolayer. Under these conditions, approxi- 
mately 50% of the original inoculum remained attached to the culture plates, 
yielding 85-90% viable cells by trypan blue exclusion. Rabbit antisera to rat and 
human LSP revealed that greater than 95% of the cells in the monolayer still 
retained LSP by indirect immunofluorescent studies (22). 
Preparation of kidney cells. The kidneys of the same animal were excised and 
placed in a sterile 100 x IO-mm petri dish containing 10 ml of Ca2+-free HBSS 
buffered with sodium bicarbonate at pH 7.4 and supplemented with 100 pg/ml of 
streptomycin and 100 units/ml of penicillin. After removing the capsule, the kid- 
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Trypsin medium (0.25%), consisting of Ca2+- and Mg”+-free phosphate-buffered 
saline containing 100 pg/ml of streptomycin and 100 units/ml of penicillin was 
maintained at 37°C. The medium was used to trypsinize the washed kidney frag- 
ments on a magnet stirrer at 37°C for 20-30 min. The undigested fragments were 
allowed to settle and the supernatant decanted. 
Trypsinization was repeated with fresh aliquots of trypsin every 15-20 min 
until most cells were released from the fragments, and the supernatants collected 
in a flask set in an ice bath. The cell suspension was centrifuged at 6OOg for 10 min 
and the supernatant discarded. 
The growth medium which consisted of Eagle’s minimum essential medium 
with Hank’s salts containing 100 pg/ml of streptomycin, 100 units/ml of penicillin, 
and 10% heat-inactivated FCS, was maintained in an ice bath. The cells were 
resuspended in growth medium and washed three times at 6OOg for 5 min. Trypan 
blue exclusion testing was performed and the percentage of viable cells ranged 
between 90 and 95%. 
The isolated epithelial cells, suspended in growth medium, were used for the 
cell cultures. Viable cells (1 x 105) were seeded into each well of a Falcon mul- 
tiwell tissue culture plate (Falcon 3008) (5 x lo4 cells/cm*) in a volume of I ml of 
growth medium. The kidney cells, like the hepatocytes, were incubated at 37°C in 
a humidified atmosphere of 5% CO, in air. The medium was changed daily. By the 
third day of incubation, 50% of the original inoculum remained attached to the 
culture plates and yielded 85-90% viable cells by the trypan blue exclusion test. 
Isolation of‘PBh4. Venous blood from patients or controls was collected in 
preservative-free heparin (1000 units/ml), diluted 1: 1 with sterile 0.9% saline, and 
layered over Ficoll-Hypaque. Following centrifugation at 4OOg for 40 min at 
room temperature, the PBM contained in the interface were washed with saline 
and centrifuged at 4OOg for 15 min. The cells were washed twice more with saline 
and centrifuged at 4008 for 10 min. Viability exceeded 95% by trypan blue exclu- 
sion and lymphocytes constituted 90-95% of the cell population with the remain- 
ing cells consisting of monocytes. The PBM were resuspended in saline, counted, 
and the final concentration adjusted to 1 x IO7 cells/ml. Sera from patients and 
controls were heat inactivated at 56°C for 45 min. 
C’ytotoxicity studies. On the third day of culture, 100 PCi of “‘Cr (sodium chro- 
mate, 1.0 &i/ml, Amersham Corp., Arlington Heights, Ill.) was added to each of 
the wells containing liver and kidney monolayers. The hepatocytes were incu- 
bated for 90 min and the kidney cells for 3 hr both at 37°C in humidified air with 5% 
CO,. After incubation, the cells were washed three times with culture medium to 
remove all excess unbound free j’Cr. In preliminary studies, washed rat hepato- 
cyte and kidney monolayers exhibited counts of 8290 t 1574 and 9356 ? 25 15 cpm 
(mean + SD of five experiments), respectively following incubation with “‘Cr. 
Additional experiments using PBM to target cell ratios of 10: 1, 20: 1, and 60: 1 
were accomplished on three patients with CAH. No cytotoxicity was seen at the 
10: 1 ratio. While cytotoxicity was elicited at the 20: 1 and 60: 1 ratios, the former 
yielded consistently higher values. PBM of patients and controls were added to 
3-day-old liver and kidney monolayer cultures at a ratio of 20: 1. Triplicate samples 
were prepared. PBM (1 x 106) in 0.1 ml of HI-WOJBA,,,, was added to the 
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labeled liver cells. Similarly, 1 x lo6 PBM in 0.1 ml of growth medium was added 
to the labeled kidney monolayers. In parallel wells, homologous or autologous 
serum, at a final concentration of 10% was added with the PBM. One set of wells 
contained only liver cells and culture medium, and another set, kidney cells and 
growth medium. PBM (1 x 106) were incubated with a previously determined 
optimal concentration of 40 pg/ml of pyrogen-free (clinical quality) calf thymosin 
fraction 5 (29) for 20 min in a water bath at 37°C. These were then added to a set of 
wells containing liver cells. A final set of wells containing liver cells was incubated 
for 30 min with rabbit antisera to human LSP, diluted 1:4 with HI-WO,/BA,,,,. 
The anti-LSP was prepared and tested for specific reactions toward LSP as de- 
scribed previously (30). In addition, the antisera was absorbed, in turn, with 
lyophilized rat plasma, rat spleen cells and kidney homogenates, and finally with 
human PBM at a 3:l-volume ratio of serum to cells (22). The anti-LSP was not 
cytotoxic for rat hepatocytes in the absence of effector cells as determined by 
trypan blue examination of hepatocytes incubated with the antisera at 37°C for 6 
hr. PBM from patients with CAH or controls were then added to these wells. 
The final volume of each well was brought to 1.5 ml by adding culture medium 
to all wells with liver cells and growth medium to the wells with kidney cells. The 
cultures were then incubated at 37°C for 6 hr in a rocking chamber in a humidified 
atmosphere containing 5% CO*. 
Following incubation, the entire reaction mixture in each well was transferred 
into a 12 x 75-mm plastic test tube (Falcon 2054) using a rubber policeman and a 
Pasteur pipette. The mixture was centrifuged at 3008 for 10 min. One-half milliliter 
of the supernatant was collected, without disturbing ‘the pellet, by using a pipet- 
man and transferred to another 12 x 75-mm glass tube. The original tube with 1 ml 
of supernatant and the cell pellet was designated the pellet tube. 
All samples were counted for their radioactivity in an AutoGamma spec- 
trophotometer, Model 5320 (Packard Instruments Co., Downer’s Grove, Ill.). 
Background counts per minute were subtracted from the supernatant and pellet 
tubes. 
Calcularions ofcytotoxiciry. The percentage of 51Cr release from labeled liver or 
kidney cells was calculated according to the following equation: 
% specific 51Cr release = 
3 x cpm in supernatant tube 
cpm in supematant tube + cpm in pellet tube 
x 100. 
Cytotoxic activity was expressed as the mean percentage & SD of 51Cr released 
from triplicate determinations. 
The cytotoxicity ratio (CR) (11) for each patient or individual CT-2 was calcu- 
lated as follows: 
% specific 51Cr release of each patient or CT-2 
% specific 51Cr release of the corresponding CT-l 
The CR of each patient and CT-2 was calculated using the single CT- 1 subject in 
each experiment. Comparison of the CR between the patient groups and the CT-2 
group was accomplished using Student’s independent t test. Changes in the CR 
within study groups were analyzed by applying Student’s dependent t test. 
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FIG. 1. Cytotoxicity ratios in chronic active hepatitis (CAH), alcoholic hepatitis (AH). compensated 
alcoholic cirrhosis (CAC), and miscellaneous liver diseases (MLD). The bracketed area represents the 
mean 2 2 SD of the CR for the 13 controls (CT-2). 
RESULTS 
Lymphocytes from 13 CT-2 subjects showed spontaneous cell-mediated 
cytotoxicity (SCMC) with a mean CR of 1.02 k 0.09 for rat hepatocytes. Positive 
evidence of cytotoxicity was determined to be a CR of 1.20 which represents 2 SD 
above the mean CR obtained in these 13 CT-2 subjects (Fig. I, Table 2). Lympho- 
cytes from 20 patients with CAH demonstrated increased cytotoxicity with a CR 
of 1.27 + 0.52. Although eight of these patients had CRs greater than 1.20, there 
was no significant difference in the CR between the 20 patients and the CT-2. 
When these patients were divided into treated and untreated groups of 10 patients 
each, the SCMC in the untreated group was significantly higher than the CT-2. 
The CR of patients with CAH on prednisone therapy did not differ significantly 
from the CT-2. 
As shown in Table 2, lymphocytes from patients with AH and CAC were 
significantly more cytotoxic for rat hepatocytes than were allogeneic normal lym- 
phocytes (P < 0.02 and P < 0.05, respectively). No significant difference in 
SCMC was noted between the CT-2 and the group of patients with miscellaneous 
liver disease, which included patients with CPH, unresolved hepatitis, and CAH 
in remission. 
LYMPHOCYTE CYTOTOXICITY IN LIVER DISEASE 431 
TABLE 2 










Number of lymphocytes Patient lymphocytes plus 








1.27 f 0.52 1.08 + 0.25 
1.23 + 0.68 1.10 + 0.28 
1.32 + 0.34” 1.05 + 0.24 
1.28 f 0.3Y 1.10 + 0.36 
1.31 f 0.w 1.03 f 0.25 
1.08 + 0.25 0.95 + 0.23 
1.02 T 0.09 0.99 -c 0.11 
1.32 + 0.58 1.27 + 0.42’ 
1.39 ? 0.70 1.32 + 0.396 
1.25 f 0.47 1.22 + 0.46 
1.37 + 0.38 1.26 5 0.3ob 
1.26 + 0.27 1.60 + 1.05 
1.18 + 0.27 1.38 c 0.46b 




10% test sera 
Nore. Results are expressed as means k SD. P values are derived from Student’s independent f test as compared 
to controls. 
” P i 0.01. 
h P < 0.02. 
p P < 0.05. 
The influence of serum factors on in vitro lymphocyte cytotoxicity was exam- 
ined in the patient groups. To begin with, none of the heat-inactivated sera from 
the various patient groups and CT-2 were cytotoxic for rat hepatocytes (Table 2). 
When the CR was determined when lymphocytes were incubated in the presence 
of 10% heat-inactivated autologous serum, as seen in Table 2, the CR was not 
significantly altered in any of the patient groups or CT-2 from the CR obtained 
with lymphocytes alone. 
When allogeneic normal lymphocytes were incubated in the presence of sera 
from the patient groups, the cytotoxic activity of the normal lymphocytes was 
significantly increased in sera from patients with MLD, CAH, and AH (Table 2). 
No such cytotoxic effect was noted when the CT-2 lymphocytes were incubated in 
homologous control sera. 
Thymosin effect on lymphocyte cytotoxicity. Incubation of PBM for 20 min with 
thymosin fraction 5 prior to addition to hepatocyte cultures decreased cytotoxicity 
in untreated CAH, and in patients with AH and CAC. This lowered SCMC at- 
tained statistical significance in patients with untreated CAH only. No significant 
alteration in the CR was noted in the 18 CT-l or 11 MLD subjects studied 
(Table 3). 
Antibody-dependent cellular cytotoxicity (ADCC). To evaluate the candidacy of 
the LSP as a target antigen in these studies, antisera to human LSP was added to 
the monolayers of rat hepatocytes. This was followed by the addition of lympho- 
cytes to the incubating wells. The CR was increased in seven CT-l subjects studied 
but not significantly altered in the eight patients with CAH that were evaluated 
(Table 4). That the antisera to human LSP reacted with LSP on the cell surface of 
rat hepatocytes has been shown previously (22). 
Target cell specificity. Lymphocytes from a total of 21 patients with CAH, AH, 
CAC, and CPH were incubated with monolayer cultures of rat kidney. There was 
no significant difference in SCMC between the patient and control groups. When 9 
of the 21 patients who demonstrated SCMC against liver cells were looked at as a 
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TABLE 3 
INFLUENCE OF THVMOSIN FRACTION 5 ON L~MPHOCYX CYTOTOXICI.TY 
CR 
(mean x SD) 
Number of ~.-.__ 
Study group subjects Lymphocytes alone Lymphocytes + thymosin 
____--- 
CAH (total) 20 1.27 i- 0.52 1.18 I?I 0.57 
CAH (treated) 10 1.23 t 0.68 1.23 2 0.75 
CAH (untreated) 10 1.32 t 0.34 1.14 + 0.35” 
AH 10 1.28 t 0.35 1 13 r 0.42 
CAC 7 1.31 rt 0.40 1.16 t 0.28 
MLD 11 1.06 2 0.23 1.13 + 0.26 
Controls (CT-l) 18 1.00 -c 0.00 1.13 k 0.29 
Cl P < 0.02, Student’s dependent t test. 
b Not significant, one-sided t test. 
group, none showed significant cytotoxic activity against kidney cells (CR 1.57 -+- 
0.31 for liver versus 1.04 L 0.08 for kidney) (Fig. 2). 
Association of cytotoxicity to duration of’ illness. Patients with CAH who 
showed in vitro SCMC had a mean duration of illness of 25.9 + 12.0 months (mean 
-+ SEM) as contrasted to 39.4 + 15.0 months in CAH patients who did not have in 
vitro cytotoxic activity. This difference was not significant. 
Correlation of cytotoxicity to biochemical tests of liver function. Analysis of 
biochemical parameters did not reveal any significant relationship between the 
serum total bilirubin, SGOT, SGPT, alkaline phosphatase, and albumin values, 
and in vitro cytotoxicity. 
DISCUSSION 
The results of these studies indicate that rat hepatocytes may be utilized to 
assess in vitro cell-mediated cytotoxicity in liver disease. In addition, the SCMC 
activity seen against rat hepatocytes in patients with CAH, AH, and CAC but not 
against rat kidney cells underscores the probable specificity of the lymphocyte 
target organ interaction. The isolation of target cells utilizing enzyme preparations 
of collagenase or trypsin has been shown not to result in appreciable changes in 
TABLE 4 





Lymphocytes alone Lymphocytes + anti-LSP 
CAH (total) 8 1.45 k 0.52 1.50 +- 0.54 
CAH (treated) 4 1.62 _f 0.69 1.81 t 0.58 
CAH (untreated) 4 1.29 f  0.28 1.19 j, 0.26 
Control (CT- 1) 7 1.00 + 0.00 1.38 i 0.40” 
Note. Mean + SD. 
” P < 0.05. Compared to lymphocytes alone, one-sided I test. 
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FIG. 2. Cytotoxicity ratios for liver versus kidney monolayer cultures. (A) In 21 patients examined: 
(B) in 9 patients with demonstrated cytotoxicity for liver cells. 
organ specific antigens located on rat hepatocyte membranes (3 1). In other inves- 
tigations of SCMC in CAH, lymphocytes from these patients demonstrated 
cytotoxicity against Chang cells isolated with trypsin (20, 32, 33). In one report, 
increased SCMC was observed when either Chang cells treated with trypsin or 
human hepatocytes isolated with collagenase were used as target cells (20). That 
the LSP and presumably other liver-specific antigens were still present on our 
target rat hepatocytes was confirmed using antisera to LSP both on the day of 
isolation and on the third day of culture. No attempt was made to insure that 
organ-specific antigens remained on the kidney cells after 3 days of culture. How- 
ever, retention of organ-specific kidney antigens has been reported following tryp- 
sinization and for an interval of at least 80 hr (34). 
Our data on cell-mediated cytotoxicity in CAH and AH support the conclusions 
of other investigations using a variety of target cells. Unlike several studies of 
lymphocyte cytotoxicity in CAC (8, 17), we were able to demonstrate that lym- 
phocytes from patients with CAC still manifest in vitro cytotoxic capability. The 
decreased in vitro cytotoxicity shown by patients with CAH on steroid therapy 
supports the findings of others (6, 7, 16, 19, 20), suggesting further that cortico- 
steroids inhibit the effector phase of lymphocyte-mediated cytotoxicity (35). 
Several mechanisms have been suggested to account for in vitro cell-mediated 
cytotoxicity in CAH and AH. The first, SCMC involves a specific interaction 
between the sensitized T lymphocyte and target cell antigen(s) with subsequent 
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injury or death of the target cell. This system appears to be antibody indepen- 
dent (36). 
It has been postulated that LSP may play a role in the pathogenesis of CAH ( 11, 
2 I,37 -40) and perhaps in AH (17). We were not able to demonstrate a decrease in 
cytotoxicity in CAH using blocking antibody to human LSP. Conceivably, the 
anti-LSP may have blocked SCMC but promoted ADCC or alternatively, the 
cytotoxicity observed in CAH may have represented a summation of SCMC and 
ADCC effect. The ADCC of nonimmune lymphocytes against rat hepatocytes was 
increased, presumably through the action of Fc-receptor K cells. This suggests 
that mechanisms other than that directed against LSP may be in play in this 
system, including cytotoxic activity directed against other liver-specific antigens 
that have been described (41, 42), or against antigens yet to be identified. It is 
possible that a postulated surface immunoglobulin-negative (slg-) Fc-receptor- 
bearing (Fc+) non-T lymphocyte (33) is the effector cell in rat liver SCMC. This 
effector cell does not require the presence of antibody and presumably would not 
be blocked by anti-LSP, if sensitized to another antigen. 
ADCC is a second mechanism proposed to account for in vitro cell-mediated 
cytotoxicity and requires the presence of an antibody specific for the target cell 
antigen and an effector cell possessing an Fc receptor (36, 43). The quantity of 
antibody required is substantially less than that needed for complement- 
dependent cytotoxicity (36). 
B-cell-enriched, but not T-cell-enriched fractions from patients with CAH have 
been shown to possess cytotoxic activity against isolated rabbit hepatocytes (12). 
The cytotoxicity was blocked by aggregated IgG suggesting that slg- , Fc+ K cells 
present in the B-cell fraction were the effector cells. However, no specific anti- 
body was identified in their sera-free system, thus leaving open the true identity of 
the effector cell. Kakumu et al. (32) also showed that PBM from patients with 
CAH were cytotoxic for Chang cells and that the effector cells were K but not B 
cells. Although the target Chang cells in their systems were not coated with 
antibody, if ADCC was the actual mechanism for the cytotoxic reaction, IgG 
antibodies against surface antigens on the Chang cells must have been present in 
their system. The IgG may have been produced by the lymphocytes or present in 
the FCS used. Vogten ef al. (21), using 51Cr-labeled avian erythrocytes coated 
with liver cell membrane lipoprotein as target cells and PBM as aggressors, 
showed increased cytotoxicity in patients with chronic active liver disease. 
Cytotoxicity was inhibited by free lipoprotein, antilipoprotein, and aggregated lg. 
A possible explanation for the ADCC-like mechanism of cytotoxicity in the 
absence of known antibody is offered by Vierling ef al. (33). They have suggested 
that in normal humans and in the absence of antibody, SCMC against Chang cells 
is mediated by slg-, Fc+ lymphocytes that are not T lymphocytes. It is not 
known if these lymphocytes are the same subpopulation as K cells. 
In the present study, incubation of allogeneic nonimmune lymphocytes in the 
presence of patient sera in MLD, CAH, and AH resulted in increased cytotoxic- 
ity, presumably ADCC, against rat hepatocytes. This suggests that sera of patients 
with MLD, CAH, and AH contain a factor(s), possibly IgG, that allows normal Fc 
receptor lymphocytes to demonstrate cytotoxic activity against target cells. The 
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enhanced cytotoxic activity of normal lymphocytes in the presence of sera from 
patients with MLD may be explained by the presence of antibody to hepatic 
antigens (38-40). 
We were not able to demonstrate significant inhibitory activity by sera from 
patients with CAH or AH on cytotoxicity by autologous lymphocytes in contrast 
to the findings of other investigators (6, 10, 19, 21). As mentioned previously, 
antibodies to hepatic antigens present in autologous sera (39) may have blocked 
SCMC and promoted ADCC. 
It is not possible to determine in the present study which mechanism or effector 
ceil is operative in in vitro cell-mediated cytotoxicity as unseparated peripheral 
mononuclear cells were used. The possible role of the monocyte cannot be ad- 
dressed as these cells were not removed from the lymphocyte population. Our 
data would suggest, however, that there is increased SCMC with either a sen- 
sitized T lymphocyte or a sIg--, Fc+ non-T lymphocyte as effector cells. These 
cells presumably operate in an antibody-free environment. It is possible, however, 
that adsorbed cytophilic antihepatocyte antibodies may have induced an ADCC 
mechanism and contributed an additive effect to the observed SCMC. While 
addition of antisera to LSP appears to promote cytotoxicity by allogeneic nonim- 
mune K lymphocytes, the presence of the antisera might not necessarily alter the 
increased cytotoxic effect of PBM from patients with CAH if both the K cell and 
the sIg-, Fc+ non-T lymphocyte are from the same population of null cells. 
The observation that thymosin fraction 5 significantly lowered SCMC in un- 
treated CAH raises the possibility that this thymic extract influenced a subpopu- 
lation(s) of lymphocytes involved directly, or perhaps indirectly, in cytotoxic 
activity. Thymosin did not effect lymphocyte viability and the SCMC of the CT-l 
and MLD was minimally increased. 
The endocrine thymus has an important regulatory role in the ontogenesis, 
function, and senescence of the T lymphoid system. The thymus produces thymo- 
sin which may act within the gland or at sites outside the thymus with induction of 
maturation and differentiation of T cells (25). Thymosin fraction 5 has been shown 
to increase T-cell counts and induce cellular immune competence in vitro and in 
vivo in a number of primary and secondary immunodeficiency syndromes (25, 
44-46). On interaction with thymosin, null cells possessing T-lymphocyte anti- 
gens can form spontaneous rosettes with sheep red blood cells (SRBC), a func- 
tional capacity of mature T cells (47). Thymosin fraction 5 consists of at least 12 
polypeptides with differing biologic activities which may act at discrete points in 
the differentiation of T cells already capable of forming SRBC rosettes (48). Thus, 
thymosin has been reported to influence the number and function of T-cell subsets 
which in turn can exert immunoregulatory control over B-cell immunoglobulin 
synthesis (49). In addition, a radiosensitive, thymosin-responsive suppressor cell 
has been described in humans (50). 
Thomas et al. (51) have shown that T-cell numbers are reduced in patients with 
CAH and that incubation with thymosin increased T-cell counts. In a similar 
fashion, we have shown that decreased T-cell counts in AH can be increased with 
thymosin (52). 
Diminished Con A-induced suppressor cell activity has been described in pa- 
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tients with systemic lupus erythematosus which was significantly reversed in 
vitro, when PBM were incubated with thymosin (53). Diminished suppressor cell 
activity has also been described in CAH accounting, perhaps, for increased 
cytotoxicity (4, 54). In addition, thymosin has been shown to enhance Con A- 
induced suppressor cell activity in patients with CAH (54). The decrease in 
cytotoxicity seen with thymosin in the present studies may reflect an induced 
suppressor cell effect or a direct alteration of the cytotoxic effector cell. 
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